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Coronary recanalization rates and changes in plasma
proteins of the fibrinolytic system were evaluated with
two preparations of recombinant tissue-type plasmino-
gen activator (rt-PA): the early formulation in liquid
excipient ("old" rt-PA) and the later lyophilized form
("new" rt-PA). The dose dependency of coronary re-
canalization and of effects on plasma proteins was eval-
uated for the new rt-Pa, Four groups of patients were
studied: Study 1,80 mg old rt-PA infused intravenously
over 3 hours (n =113); Study A, 80 mg new rt-PA over
3 hours (n = 47); Study B, 100 mg new rt-PA over 3
hours (n = 83); and Study C, ISO mg new rt-Pa over
6 hours (n = 62).
With equal doses of 80 mg, coronary recanalization
rates at 90 minutes of infusion, determined angiograph-
ically, averaged 62% (Study I) and 45% (Study A) with
no overlap of 95% confidence limits. Increasing the dose
of the new rt-PA to 100 mg, recanalization rates at 90
minutes averaged 71% (Study B), similar to those ob-
Two randomized, placebo-controlled studies (1,2) in pa-
tients with acute myocardial infarction demonstrated that
recombinant tissue-type plasminogen activator (rt-PA) is
superior to streptokinase in restoring patency to occluded
infarct-related coronary arteries , The initial rt-PA was
produced on a small scale to provide the opportunity for
clinical evaluation. It was formulated in a liquid excipient
with limited shelf half-life and storage conditions. The en-
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served in Study 1. An increase to ISO mg resulted in
higher recanalization rates at 30 minutes of infusion,
42% compared with 24% in Study I with no overlap of
95% confidence limits, and comparable rates at 90 min-
utes, 76 versus 62%. A linear trend test indicated a
significant relation (p < 0.01) between the dose of the
new rt-PA and the rate of coronary recanalization at 30,
60 and 90 minutes of infusion. The new rt-PA affected
plasma proteins of the fibrinolytic system less than the
old form. There was a dose-dependent relation (p <
0.001) in the effect of the new rt-Pa on the plasma pro -
teins. The frequency of bleeding complications was sim-
ilar in the four study groups.
These results indicate that the new rt-PA is less potent
than the old rt-PA, in relation to both coronary reper-
fusion and systemic fibrinogenolysis. A higher and longer
dosage regimen caused more rapid recanalization with
similar effects on fibrinogenolysis.
(J Am Coli Cardiol 1987;10:479-90)
couraging results of three clinical trials (1-3) prompted
changes in the manufacturing process that would allow large
scale production. Lyophilization was introduced to increase
half-life and allow room temperature storage. The initial
small scale rt-PA, referred to as " old rt-PA," consisted
predominantly of two chain molecules, whereas the large
scale rt-PA , referred to as " new rt-PA, " consists mainly
of single chain molecules. Because the production method
differed in important aspects, comparability ofthe two form s
of rt-PA in terms of reperfusion potency and effects on the
fibrinolytic system could not be assumed, The Thrombolysis
in Myocardial Infarction (TIMI) Study Group compared the
two form s of rt-PA in con secutive studies of patients with
acute myocardial infarction.
Methods
Selection of patients. To be eligible for treatment, pa-
tient s had to satisfy the following inclusion criteria: I) age
0735-1097/87/$3 .50
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< 76 years; 2) chest pain characteristic of myocardial isch-
emia for ;:::30 minutes ; 3) ST segment elevation ;:::0.1 mV
in at least two leads of the electrocardiogram reflecting a
single myocardial region; 3) elapsed time from onset of
ischemic pain to recruitment :'57 hours; 4) angiographically
documented ;:::50% obstruction (study I) or complete or
almost complete obstruction (TIMI perfusion grade 0 or I
[I) in open label studies A, B and C) of the infarct-related
artery .
Patients were excluded for the following reasons: I) shock
despite vasopressor therapy; 2) past or present bleeding dis-
order or significant gastrointestinal bleeding; 3) oral anti-
coagulation therapy; 4) left bundle branch block; 5) pros-
thetic heart valve; 6) dilated cardiomyopathy; 7) uncontrolled
hypertension (diastolic pressure> 120 mm Hg); 8) signifi-
cant surgical procedure or prolonged resuscitation within
the last 2 weeks; 9) cerebrovascular accident or severe trauma
within the last 6 months; 10) childbearing age; II) previous
coronary artery bypass surgery ; and 12) serious advanced
illness .
Study groups. Four groups of patients were evaluated
in the following studies:
Study 1: rt-PA Gl102l (old form) was infused intrave-
nously over 3 hours in doses of 40, 20 and 20 mg in suc-
cessive hours. The dose at 90 minutes (time of final angio-
graphic evaluation for recanalization) was 50 mg.
Study A: rt-PA GI1035 (new form) was infused in the
same dosage regimen over 3 hours. The dose at 90 minutes
was 50 mg.
Study B: The dose of rt-PA G 11035 was increased to 60,
20 and 20 mg hourly over 3 hours with an initial bolus of
6 mg. The dose at 90 minutes was 70 mg.
Study C: rt-PA G11044 (the same preparation as G 11035
but packaged in 50 mg instead of 20 mg doses) was infused
in doses of 90, 20, 10, 10, 10 and 10 mg hourly over a
time period of 6 hours with an initial bolus of 9 mg. The
dose at 90 minutes was 100 mg.
In all four studies. a heparin infusion (1,000 U/h) was
begun I hour after a bolus injection (5,000 U) and initiation
of the rt-PA infusion . The heparin dose was adjusted to keep
the level of the partial thromboplastin time l lfz to 2 times
above the upper limit of the normal value. The study was
approved by the human research review committee at each
participating institution. All patients gave signed, informed
consent.
Study Design
Cardiac catheterization. Contrast left ventriculography
was performed in the right anterior oblique projection. The
coronary artery system remote from the infarct zone was
visualized first, followed by cineangiography of the vessel
supplying the infarct zone. Angiographic projections were
standardized among clinical sites. Nitroglycerin (200 /-tg)
was injected selectively into the infarct-related artery in
Study l , but not in Studies A, Band C. If the coronary
obstruction persisted, rt-PA was infused intravenously in
the doses indicated previously . Cineangiography of the in-
farct-related coronary artery was repeated at 30, 60 and 90
minutes after the initiation of the intravenous rt-PA infusion.
Immediately before the infusion of rt-PA and after 90 min-
utes of therapy, orthogonal cineangiograms of the infarct-
related coronary artery were obtained to permit quantitative
analysis of the degree of narrowing.
Restoration of arterial patency was evaluated, both at
the clinical sites and at the radiographic core laboratory
according to predetermined definitions of reperfusion (I).
In brief, grade 0 represents no anterograde flow, grade I
penetration of dye without perfusion, grade 2 partial per-
fusion with slowed opacification of the distal vessel or de-
layed clearance and grade 3 complete perfusion with prompt
(normal) clearance. The baseline severity of coronary artery
disease was also determined at the core laboratory by visual
assessment of the percent reduction in luminal diameter of
each coronary artery and its major branches . Quantitative
angiography of the infarct-related artery was used to assess
the percent reduction in luminal diameter and minimal di-
ameter in millimeters of the infarct-related artery at baseline
and at 90 minutes of rt-PA infusion by methods described
previously (4-6) . Measurements of left ventricular ejection
fraction from the ventriculogram were obtained by the area-
length method of Sheehan et al. (7) .
Postcatheterization care. In Study 1, subsequent to
coronary cineangiography at 90 minutes, patients were
transported to the coronary care unit. In-dwelling vascular
sheaths were secured for removal the following day. The
heparin infusion, begun 1 hour after initiation of the rt-PA
infusion, was continued for 8 to 10 days until repeat cardiac
catheterization was performed . Subsequently, patients re-
ceived aspirin (325 mg three times daily) and dipyridamole
(75 mg three times daily) orally for at least 6 months.
IIIStudies A, Band C, in addition to the on-going heparin
infusion, aspirin (80 mg one time daily) and dipyridamole
(75 mg four times daily) were given immediately after trans-
fer of the patient from the cardiac catheterization laboratory
to the coronary care unit. Heparin was continued for ap-
proximately 5 days. Subsequently, aspirin (325 mg three
times daily) and dipyridamole (75 mg three times daily)
were given for at least 6 months . Percutaneous transluminal
angioplasty was introduced to the protocol if reperfusion
had occurred during the acute state and the coronary lesion
was considered suitable for angioplasty . The procedure was
performed 18 to 48 hours after initiation of the rt-PA in-
fusion .
End points. The primary end point considered here was
the proportion of patients with TIMI grade 2 or 3 reperfusion
at 90 minutes who had grade 0 or I perfusion initially.
Secondary end points included reperfusion at 30 and 60
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minutes, frequency and severity of hemorrhagic compli-
cations, changes in coagulation variables and clinical find-
ings of coronary reocclusion at 24 hours.
Coagulation tests. Measurements of the plasma levels
of fibrinogen, plasminogen activity and fibrin(ogen) deg-
radation products in blood samples collected at baselineand
at 3, 5 and 27 hours after initiation of thrombolytic therapy
were made in the Coagulation Core Laboratory established
at the Thrombosis Research Center, Temple University.
Philadelphia. Fibrinogen levels were measured in citrated
plasma obtained from blood collected in tubes containing
250 iLg/ml of aprotonin (Trasylol, FBA Pharmaceuticals)
by the precipitation method of Martinek and Berry (8).
Plasma plasminogen was measured in citrated plasma using
chromogenic substrate, S-2251 (Kabi Diagnostica. Stock-
holm) by the method of Friberger and Knos (9) and ex-
pressed as percent activity compared with pooled normal
plasma. Fibrin(ogen) degradation products were measured
by the Thrornbo-Wellcotest method using latex particles
coated with antibodies against fibrinogen fragments D and
E (Wellcome Diagnostics, Temple Hill. Dartford, England)
in serum harvested from 2 ml of blood collected in tubes
containing thrombin (20 NIH units), soybean trypsin inhib-
itor (3.670 NF units) and protaminesulfate (50 iLg. Eli Lilly
Company).
Classification of bleeding. The Mortality and Morbidity
Classification Committee reviewed case reports of all pa-
tientswho had a bloodtransfusion. a decrease in hemoglobin
2:3.0 gldl or an observed blood loss. They classified the
hemorrhage as " major" if there was a decrease in hemo-
globin > 5 g (or> 15% decrease in hematocrit) or any in-
tracranial bleeding. Hemorrhage was classified as "minor"
I) if there was an observed blood loss and a decline in
hemoglobin of 3 to 5 g (or in hematocrit of 10 to 15%)
from admission to the bleeding event. 2) gross hematuria
Of hematemesis (> 120 ml), even if the decrease in hemo-
globin or hematocrit was < 3 g Of < 10%. respectively. or
3) it was classified as " loss. no site" . identified and ana-
lyzed as minor if there was an unobserved loss 2:4 g hemo-
globin or 2:12% in hematocrit. The Committee also defined
the primary and secondary sites.
Statistical analysis of data. Because patients were not
randomly assigned to the different study groups. t tests and
tests of proportion are not appropriate statistical tests for
intergroup comparison. Instead, 95% confidence intervals
were calculated. For descriptive purposes, values may be
considered different if the 95% confidence limits did not
overlap.
At each time point of angiographic assessment. at 30.
60 and 90 minutes, a linear test of trend was performed to
test the relation of time and dose of rt-PA to reperfusion .
The dependent variable was the percent of patients with
perfusion grade 2 or 3, and the independent variable was
the dose of rt-PA received up to that time point. This test
is equivalent to testing the slope of a simple linear regres-
sion. A statistically significant result means the slope is
different from zero. and that there is correlation between
the independent and dependent variables. Linear tests of
trends were also performed to test the relation between the
dose of rt-PA (independent variable) and the levelof plasma
proteins of the fibrinolytic system (dependent variable) and
the relation between levels of plasma proteins (independent
variable) and bleeding events (dependent variable). For in-
tragroup comparison. the paired t test was used. A (p) value
< 0.05 was considered statistically significant.
Results
Patient data (Table I). A total of 344 patients were
studied, 143 in Study I. 48 in Study A, 88 in Study Band
65 in Study C. In this report, 305 patients with perfusion
grades 0 or I of the infarct-related artery at baseline were
considered. The data were analyzed for both patient groups.
The interpretation of the data did not differ.
The baseline clinical data did not differ among the four
study groups with regard to the variablesreported. The mean
patient ages varied between 54 and 57 years; the majority
of patients were male. Approximately 50% of the patients
had a history of hypertension or angina pectoris, or both,
and 16% had had a prior myocardial infarction. The left
anterior descending or the right coronary artery each was
the infarct-related vessel in approximately 45%; the circum-
flex coronary artery was the infarct-related vessel in about
10%. More than 50% of patients had one vessel disease and
approximately 25% had two vessel disease. The minimal
coronary diameter at baseline, determined by quantitative
analysis in the radiographic core laboratory. averaged be-
tween 0.01 and 0.02 mm. Left ventricular ejection fraction
was moderately decreased. Heart rate and blood pressure
were within normal limits. The mean value of the interval
between clinical onset of infarction and initiation of rt-PA
infusion ranged between 4.2 and 5.1 hours.
Reperfusion rates. Table 2 and Figure I demonstrate
the coronary reperfusion rates at 30, 60 and 90 minutes of
rt-PA infusion for the different groups. The patency rates
obtained in Study I with the old form of rt-PA averaged
62% at 90 minutes. At this time. 50 mg of rt-PA had been
infused. Using the same dosage schedule with the new form
of rt-PA, the patency rates were lower at 30 minutes (13
versus 24%), at 60 minutes (30 versus 48%) and at 90
minutes (45 versus 62%). When the dose of new rt-PA was
raised from a total of 80 mg in Study A to 100 mg in Study
B (from 50 to 70 mg 140%J at 90 minutes) and an initial
bolus of 6 mg was given, the coronary patency rates were
similar to those observed with the 80 mg regimen of the
old form of rt-PA (Study I). With the highest dose schedule
of 150 mg rt-PA (Study C). which included an initial bolus
of 9 mg. the patency rates (42%) at 30 minutes were higher
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Table l. Patient Data: Patients With Grade 0 or I Coronary Perfusion Pretreatment
Baseline Study
Characteristics A B C
Patients (n) 113 47 83 62
Age (yr) 56.3 54.0 57.3 55.7
< 65 years (%) 79.6 80.9 73.5 77.4
Male (%) 76.1 80.9 80.7 83.9
History (%)
Hypertension 52.2 36.2 43.4 41.9
Prior myocardial infarction 16.0 14.9 14.5 17.7
Congestive heart failure 0.9 0.0 0.0 4 .8
Angina pectoris 46.9 48.9 48.2 46.8
Site of infarct (%)
Anterior 43.4 48.9 55.4 64.5
Inferior 54.9 46.8 43.4 32.3
Lateral 1.8 4.3 1.2 3.2
Infarct artery-core laboratory (%)
Right coronary 48.7 42.6 41.0 33.9
Left anterior descending 38.9 42.6 47.0 58.1
Left circumflex 12.4 14.9 12.0 8. 1
Number of vessels with > 70% stenosis (%)
One 61.1 61.7 56.6 66. 1
Two 29.2 23.4 31.3 24.2
Three 9.7 14.9 12.0 9.7
% Stenosis 99.6 99.5 99.8 (82) 100.0 (61)
Minimal coronary diameter (mm) 0.01 0.02 0.01 (82) 0.01 (61)
Ejection fraction (%) 48.8 (93) 48.1 (42) 46.3 (79) 45.3 (54)
Creatine kinase (total [Uzliter] at admission) 255 (102) 243 (42) 113 (77 ) 154 (58)
Heart rate (beats/min) 79.6 77.9 75. 1 75.7
Systolic blood pressure (mm Hg) 133.7 131.5 132.5 131.7
Symptom onset to treatment initiation (hours) 4.8 5.1 4.6 4.2
rxcc Vol. 10. No. 3
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Data represent mean values; 95% confidence limits. not shown. do overlap between studies in all of the
characteristics. Numbers in parenthesis after values represent denominator if less than the number treated . CK
= creatine kinase.
than observed among the other gro ups. Reperfusion rates
differed between Studies A and Cat 30, 60 and 90 minu tes
(no overlap of 95% confidence limits) and also between
Studies A and B at 60 and 90 minutes, between Studies I
and A at 60 minutes and between Studies I and C at 30
minutes . Significant relations were observed between the
doses of new rt-PA and the rates of coronary recanalization.
On the basis of a linear trend test at 30, 60 and 90 minutes
afte r initiation of infusion, the recanalization rates were
higher with increasing dose (p < 0.001 [30 and 60 minutes];
p < 0.01 [90 minutes]) .
Coronary reocclusion within 24 hours after rt-PA infu-
sion. suggested by clinical findings of recurrent ischemia
such as severe persistent chest pain , new ST segment ele-
vatio ns or new creatine kinase (CK) or MB CK release did
not statistically differ. They occurred in 6% (Study I), 10%
Table 2. Coronary Recanalization Rates in Patients With Grade 0 or I Perfusion Pretreatment (Angiographic Core Laboratory)
Study I Study A Study B Study C
Duration (n = 113) (n = 47) (n = 83) (n = 62)
of rtoPA Dose Recan 95% Dose Recan 95% Dose Recan 95% Dose Recan 95%
Infusion (mg) (%) CL (rng) (%) CL (mg) (%) CL (rng) (%) CL
Minutes
30 20 24 16 to 32 20 13 3 to 23 33 24 15 to 33 50 42 30 to 54
60 40 48 39 to 57 40 30 17 to 43 60 57 46 to 67 90 68 56 to 79
90 50 62 53 to 71 50 45 31 to 59 70 71 61 to 81 100 76 65 to 86
180 80 80 100 120
Hours
6 150
95% CL = 95% confidence limits; Recan = recanalization.
JACC Vol. 10. No.3
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Figure I. Coronary reperfusion rates during recombinant tissue-
plasminogen activator (rt-PA) infusion are shown for the different
groups. The doses at the 30, 60 and 90 minute time points, re-
spectively, were as follows: (Study I ) (x) 20, 40 and 50 mg old
rt-PA; (Study A) (,6,) 20, 40 and 50 mg new rt-Pa : (Study B) (0)
33, 60 and 70 mg new rt-Pa: (Study C) (e ) 50, 90 and 100 mg
new rt-PA. Compared with Study I . there was no overlap of the
95% confidence limits with Study A at 60 minutes and with Study
C at 30 minutes; compared with Study A there was no overlap
with Study C at all time points after baseline and no overlap with
Study B at 60 and 90 minutes.
(Study A), 17% (Study B) and 6% (Study C); the 95%
confidence limits overlapped between all measurements.
Coagulation data. Table 3 shows the absolute values
of plasma levels of fibrinogen, plasminogen and fibrin deg-
radation products in patients treated with the four regimens;
Figures 2 and 3 indicate the residual levels (100 x post/
preinfusion).
Fibrino gen levels. At 3 hours after initiation of the drug
infusion, the mean residualfibr inogen level in patients treated
with 80 mg of old rt-PA (Study I) was 73% (Fig. 2). In
comparison. the levels were higher in patients receiving 80
mg (98%) and 100 mg (92%) of new rt-PA (Studies A and
B) (no overlap of 95% confidence limits). At 5 hours of
infusion the residual fibrinogen levels also were higher in
patients receiving 80 mg (96%) (Study A) and 100mg (86%)
(Study B) than with 80 mg of old rt-PA (65%) (no overlap
of 95% confidence limits). In contrast, the residual fibrin-
ogen levels at 3 (78%) and 5 (71%) hours in patients treated
with the highest dose (150 mg) of new rt-PA (Study C)
were similar to those with 80 mg of old rt-PA (Study I) .
At 5 hours, 18% of the patients with the 80 mg old rt-PA
regimen had fibrinogen levels < 150 mg/dl compared with
0, 4 and 17% of patients with the 80. 100 and 150 mg
regimens of new rt-PA, respectively. Thus, compared with
patients receiving old rt-PA, the decline in fibrinogen levels
was strikingly less in patients receiving the 80 and 100 mg
Table 3. Proteins of the Fibrinolytic System in Patients With Grade 0 or 1 Perfusion Pretreatment
Blood Samplin g. After Initiation of rt-PA Infusion *
Fibrinogen Degradation Products
Fibrinogen (mg%J Plasminogen (%)t (JLg/ml)
Study 0 3 5 27 0 3 5 27 0 3 5 27
n 97 96 97 94 99 96 96 94 98 97 94 92
Mean 374 270 240 32 1 99 36 43 60 3 117 100 27
SO 9 1 SI 82 8 1 IS 14 13 14 13 14 1 106 5 1
p Valuer < 0 .00 1 < 0. 00 1 < 0.00 1 < O.tlOl < 0 .00 1 < 0 .00 1 < 0 .00 1 < 0 .00 1 < 0 .00 1
A
n 45 4 1 40 4 1 45 42 44 41 45 40 4 1 41
Mean 325 3 14 298 359 96 59 68 69 2 47 27 18
SO SO 62 67 103 15 19 12 14 6 115 75 65
p Valuef 0 . 10 0 .04 0 .09 < D.OOI < 0.00 1 < 0. 00 1 0 .02 0 .03 0 .09
B
n 79 74 78 69 SO 76 78 70 80 73 73 65
Mean 349 319 295 32S 99 5 1 60 68 8 104 56 13
SO 85 86 85 85 18 17 16 16 46 188 90 2 1
P Valuer < 0 .00 1 < 0. 001 0 .02 < D.OOI < O.DOI < 0.00 1 < 0. 00 1 < 0 .00 1 NS
C
n 46 43 41 35 47 47 46 42 46 40 4\ 34
Mean 310 230 207 282 99 41 43 62 6 132 112 3 1
SO 91 70 60 79 21 16 16 14 19 202 161 52
p Valuer <O(lOl < 0 .00 1 NS < 0.00 1 < 0 .00 1 <0.001 < 0 .00 1 < 0 00 1 0 .005
*At O. 3. 5 and 27 hours. tPercent activity compared with normal pooled plasma. t lndicates difference compared with 0 (preinfusion value). n ==
number of patients .
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Figure 2. Residual levels (%) of fibrinogen at 3, 5 and 27 hours
after initiation of the rt-PA infusion are shown for the different
studies. Number of patients are indicated in Table 3. Compared
with Study I (x), there was no overlap of the 95% confidence
limits with Study A (6) at all time points after baseline and no
overlap with Study B (0) at 3 and 5 hours. (e) Study C.
Figure 3. Residual levels (%) of plasminogen at 3. 5 and 27 hours
after initiation of the rt-PA infusion are shown for the different
studies. Number of patients are indicated in Table 3. Compared
with Study I (X), there was no overlap of the 95% confidence
limits with Studies A (6) and B (0) at all time points after
baseline. (e) Study C.
doses of new £l-PA, but comparable at the highest dose .
There was an inverse relation between the dose of new rt-
PA and fibrinogen level s. At the 3 and 5 hour time point s
the fibrinogen level s were higher at the lower doses (p <
0.001 for slope of regression of dose and fibrinogen ).
Plasminogen activity. The declines in plasma plasmin-
ogen activity in Study A and B patients treated with 80 and
100 mg of new £l-PA were less than in Study I patients
treated with 80 mg of old £l-PA; at the 150 mg dose of new
£l-PA (Study C) the changes were comparable (Fig . 3). At
5 hours , the mean residual plasma plasminogen levels were
higher in patients treated with 80 mg (7 1%) and 100 mg
(61%) of new £l-PA compared with those treated with old
£l-PA (44%) (no overlap of 95% confidence limits); at 150
mg of new rt-PA , the level s were similar (48%) to those
observed in Study I. An inverse dose-dependent effect was
noted in plasminogen level s in patients receiving new rt-
PA. At the 3 and 5 hour time points the plasminogen levels
were higher at the lower doses (p < 0.001 for slope of
regression of dose and plasminogen).
Fibrin(ogen) degradation products (Table 3). Plasma
levels offibrin(ogen) degradation products (FOP) were mea-
sured as a reflection of the action of plasmin generated from
the activation of plasminogen by rt-PA . The FOP levels
(Fig. 4) at 5 hours in patients treated with 80 mg of old £l-
PA (loo J-Lg/ml ) were much higher compared with those
treated with the same dose (28 J-Lg/ml) or 100 mg (56 J-Lg/ml)
of new rt-PA (no overlap of 95% confidence limits), but
comparable with those receiving 150 mg of new £l-PA (112
J-Lg/ml ). There was a relation betwe en the dose of new rt -
PA and level s of FOP. Based on the slope of the regre ssion
of dose and FOP at the 3 (p = 0 .04 ) and 5 hour (p <
Figure 4. Fibrin(ogen) degradation products at 3, 5 and 27 hours
after initiation of the rt-PA infusion are shown for the different
studies. Number of patients are indicated in Table 3. Compared
with Study I (x), there was no overlap of the 95% confidence
limits with Study A (6) at 3 and 5 hours and with Study B (0)
at 5 hours. (el Study C.
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Ta ble 4. Percentage of Patients With Bleeding Events by Selected Levels of Plasma Proteins of the Fibrinolytic System in Patients
With Grade 0 or I Perfusion Pretreatment
Study
A B C Total
Plasma
Protein HEM n % HEM n % HEM n % HEM n % HEM n %
Fibrinogen
Total no. of patients 97 40 78 41 256
o to 149 mg% /I 17 65 0 0 0 2 3 67 4 7 57 17 27 63
150 to 249 mg% 9 37 24 3 10 30 I) 22 4 1 13 24 54 34 93 37
2= 250 mg% 15 43 35 10 30 33 23 53 43 3 10 30 51 136 38
P Value* 0.19 0.91 0,47 0.14 0.30
Plasminogen
Total no. of patients 96 44 78 46 264
< 50% 27 72 38 0 2 0 10 17 59 19 32 59 56 123 46
2= 50% 7 24 29 16 42 38 24 61 39 5 14 36 52 141 37
P Value* 0.22 0.03 0.58 0.05 0.02
FDP
Total no. of patients 94 41 73 41 249
Oto 99 JLglml 10 45 22 II 37 30 21 56 38 7 21 33 49 159 31
100 to 399 JLg/ml 21 45 47 I 3 33 9 14 64 10 17 59 4 1 79 52
2=400 JLg/ml 3 4 75 0 I 0 3 3 tOO 2 3 67 8 I I 73
P Value* 0.003 0.81 0.006 0.22 < 0 001
*Slope of regression of plasma proteins and bleeding events. FDP = fibrin(ogcn) degradation products; HEM = number of patients with hemorrhagic
events; n = number of patients with plasma proteins within a selected range.
0 .00 I) time points , FOP levels were higher at the higher
dose s .
Plasma proteins and bleeding (Table 4) . The relation
between plasma proteins of the fibrinolytic system 5 hours
after initiation of rt-PA infusion and hemorrhagic compli-
cations was evaluated. In Study I , the frequency of bleeding
increased with incre asing level s of FOP (p = 0.003 for
slope of regression) . In Study A, changes in plasma proteins
were much less compared with those observed in Studies
I , Band C (Table 3) and similar relations were not noted .
In Studies Band C, the frequency of bleeding tended to be
greater in patients who had marked changes in plasma pro-
teins . However, this relation was statistically significant
only with regard to FOP in Study B (p = 0 .006 ) and to
plasminogen in Study C (p = 0.05 for slope of regression ).
Combining the data of the four study groups , the frequenc y
of bleeding events increased with decreasing plasma level s
of plasminogen (p = 0.02 ) and with increasing levels of
FOP (p < 0.001 for slope of regre ssion).
Plasma proteins and reperfusion. The relation between
changes in plasma levels of the measured proteins and re-
perfusion was explored in patients treated with both forms
of rt-PA; no significant differences were noted between those
with and without successful repcrfusion. However, the re-
lation between decreases in plasma fibrinogen levels (at 3
hour s) and rates of coronary reperfusion (at 90 minutes)
differed between the old and new forms of n-PA. At re-
canalization rates of 62% (old rt-PA, Study I) and 45%
(new rt-PA , Study A) , fibrinogen level s had decreased by
28 and 2%, respectively. At comparable recanalization rates
of 62% (Study I) and 71% (Study B), decreases in plasma
fibrinogen levels averaged 28 and 8%, respectively . Only
with the highest dose regimen were the rates of recanali-
zation (62% [Study I] and 76% [Study C)) and decreases
in fibrinogen leve ls (28 and 22%, respectively) comparable
between old and new rt-PA .
Bleeding complications (Table 5). Considering hem-
orrha gic events, it should be emphasized that cardiac cath-
eterization was performed before and during thrombolysis,
and that percutaneous transluminal angioplasty within 18 to
48 hours was considered in Studies A, Band C. Further,
patients received heparin (bolu s and infusion) and aspirin
and dipyridamole (except in Study I) concomitantly with
the thrombolytic agent. Although the frequency of hemor-
rhagic events tended to increa se in Studie s B (42 %) and C
(47%) compared with Studies I (35%) and A (36%), the
95% confidence level s overlapped among the four studies.
Bleeding at puncture sites of the femoral artery and vein
and at other puncture sites predominated, ranging between
19 and 42% in the four studies. Major gastrointestinal bleed -
ing events were rare (1 to 3%) . In general , gastrointestinal
bleeding could be controlled with conventional methods .
One patient who developed melanotic stool while on aspirin
therapy underwent emergency surgery because of erosion
of the gastric artery. He succumbed during gastric resection;
this was the only death attributable to a bleeding compli-
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Table 5. Bleeding Complications in Patients With Grade 0 or I Perfusion Pretreatment
Study
A B C Total
Characteristic n % n o/c n o/c n % n o/c
No. of patients 113 47 83 62 305
Type of loss
Major 15 13 5 II 17 20 15 24 52 l7
Minor* 25 22 12 26 18 22 14 23 69 23
Total 40 35 17 36 35 42 29 47 121 40
Catheterization or puncture site
Major (primary) lO 9 3 6 10 12 13 21 36 12
Minor (primary) 18 16 6 13 14 17 13 21 51 l7
Total 28 25 9 19 24 29 26 42 87 28
Gastrointestinal
Major (primary) I 1 0 0 2 3 4 1.3
Minor (primary) 0 0 3 6 I 2 5 1.6
Unknown
Major 4 4 0 0 2 2 0 0 6 2.0
Minor 3 3 2 4 I I 0 0 6 2.0
Other
Major (primary) 0 0 2t 4 4t 5 0 0 6 2.0
Minor (primary) I I I 2 0 0 0 0 2 0.7
Transfusion§ 25 22 7 15 19 23 19 31 70 23
I Unit 2 1.8 I 2.1 6 7.2 5 8.1 14 4.6
>2 Units 23 20.4 6 12.8 13 15.7 14 22.6 56 18.4
*Includes minor blood loss without site. rOne retroperitoneal, one femoral artery laceration. tOne intracranial, two surgical. one skin graft site.
§Related to bleeding event.
cation. There was one intracranial hemorrhage in Study B.
The patient died 8 months after rt-PA treatment. Other bleeding
events were hematuria, hemoptysis and oozing from the
gums. Blood transfusions, related to bleeding events, were
given in 22, 15,23 and 31% of the patients in the four study
groups, respectively; between 13 and 23% of patients re-
ceived 2:2 units.
Complications during the first 24 hours other than
bleeding and cardiac events: clinical course (Table 6).
The infusion of the old form of rt-PA and of the three dose
regimens of the new form of rt-PA was well tolerated. There
was a trend toward increasing frequency of fever and chills
with increasing doses of new rt-PA (overlap of 95% con-
fidence limits). Nausea and vomiting, frequently observed
events during acute myocardial infarction, occurred on av-
erage in 25 to 45% of patients. None of the patients de-
veloped anaphylaxis.
During the hospital course, clinical and electrocardio-
graphic findings of recurrent myocardial ischemia including
coronary reocclusion occurred on average in 21 %, (Study
I), 8.5% (Study A), 20% (Study B) and 10% (Study C) of
patients (overlap of 95% confidence limits). Average peak
plasma creatine kinase levels varied between 2,411 and
3,087 U/liter (overlap of 95% confidence limits). The in-
Table 6. Complications During the First 24 Hours Other Than Bleeding and Cardiac Events in Patients With Grade 0 or I
Perfusion Pretreatment
Study
A B C Total
Characteristic n % n % n % n % n %
No. of patients 113 47 83 62 305
Urticaria I 0.9 0 0.0 0 0.0 I 1.6 2 0.7
Fever or chills 5 4.4 3 6.4 7 8.4 7 11.3 22 7.2
Nausea or vomiting 44 38.9 12 25.5 34 41.0 28 45.2 118 38.7
Convulsions I 0.9 I 2.1 I 1.2 0 0.0 3 1.0
Anaphylaxis 0 0.0 0 0.0 0 0.0 0 0.0 0 0
JACC Vol. 10, No. }
September 1987:479-90
MUELLER ET AL
DIFFERENCES IN TISSUE·TYPE PLASMINOGEN ACTIVATORS
487
hospital death rates were 5,2% (Study I), 4.3% (Study A),
8.4% (Study B) and 4,8% (Study C),
Discussion
New versus old rt-PA. The TIMI Study demonstrates
in consecutive groups of patients with acute myocardial
infarction that the reperfusion potency of the two form s of
recombinant tissue-type plasminogen activator (rt-PA), ob-
tained by different production techniques, is different. At
the 80 mg dose regimens, coronary reperfusion with the
new form of rt-PA was less frequent. and it induced less
systemic fibrinogenolysis than did the old form of rt-PA.
At comparable recanalization rates, achieved with 80 mg
of old and 100 mg of new rt-PA, systemic fibrinogenolysis
was much less with the new form. whereas at the highest
dose of new rt-PA tested (150 mg), systemic fibrinogeno-
lysis was similar to that observed with 80 mg of old rt-PA.
The data also demonstrate a time- and dose-dependent re-
lation between rt-PA and the potency of coronary recanal-
ization and effects on fibrinogen , plasminogen and fi-
brin(ogen) degradation products.
Mechanisms of differences between two forms of rt-
PA. Differences in pharmacokinetics. The differences in
reperfusion potency and in effects on plasma proteins of the
fibrinolytic system between the two rt-PA preparations are
explained, at least in part, by differences in pharmacoki-
netics. The plasma half-life of the new form of rt-PA is
shorter than that of the old form. Initially, Korninger et al.
(10) studied the turnover of t-PA from human melanoma
cell cultures (mt-PA) in rabbits, The half-life was approx-
imately 2 minutes because of the rapid elimination of mt-
PA by the liver. The rapid disappearance of mt-PA was
confirmed in animal experiments (II). in normal volunteers
(12) and in patients with acute myocardial infarction (13).
Collen et al (14) demonstrated in the rabbit that both prep-
arations, mt-PA and rt-PA, had a similar half-life of ap-
proximately 2 minutes. These results were confirmed for rt-
PA in the dog (15) and baboon (16) models. Verstraete et
al (17) evaluated the turnover of the old form of rt-PA in
normal volunteers and patients with chronic arterial occlu-
sive disease, acute thromboembolic manifestations or acute
myocardial infarction. The half-life of rt-PA was bi-expo-
nential with an alpha phase of 6 minutes and a beta phase
of approximately 60 minutes. The turnover of the new form
of rt-PA was studied in the rhesus monkey. The data re-
vealed an alpha phase of 2.8 minutes and a beta phase of
20 minutes (18). Garabedian et al (19) confirmed in patients
with acute myocardial infarction that the turnover of the
new rt-PA was faster than that of the old form. The alpha
phases averaged 4.3 and 5.2 minutes and the beta phases
36 and 46 minutes, respectively. These investigators also
demonstrated that at comparable infusion rates, the plasma
levels of the new rt-PA were approximately 35% lower than
those obtained with the old form.
The find ings just summarized are consistent with the
results of the clinical studies performed by the TIMI in-
vestigators. Using the same dose regimen for the old and
new forms of rt-PA, coronary recanalization rates were 30
to 40% lower with new rt-PA (Fig. I) . An increase in dose
of new rt-PA by 40% during the initial 90 minutes of in-
fusion resulted in recanalization rates similar to those ob-
served with the lower dose of old rt-PA. Although data
regarding rt-PA plasma levels are not available here, a re-
lation between the dose of new rt-PAand the rate of coronary
recanalization has been demonstrated. At each of the time
points of rt-PA infusion, at 30, 60 and 90 minutes. coronary
recanalization rates increased significantly with increasing
doses. An improvement in coronary recanalization rates with
increasing doses was also suggested in patients with acute
myocardial infarction. using the old form of rt-PA (20), and
recently by Garabedian et al. (19). using the old and new
forms. In addition to the dose-dependent relation for coro-
nary recanalization observed in our studies, a similar dose-
dependent effect was noted with respect to systemic fibrin -
ogenolysis.
The reasons for the diff erences in pharmacokinetics he-
tween the old and new f orms of rt-PA are line/ear . They
do not seem to be related to molecular structure. The old
form of rt-PA is more than 90% double chain molecules.
resulting from proteolytic cleavage of the single chain mol-
ecule. whereas the new form is predominantly single chain
molecules. Infusion of t-PA from human melanoma cell
tissue cultures into rabbits revealed no difference in phar-
macokinetics (10) between single and double chain material.
Studies of the new form of rt-PA in the rhesus monkey
demonstrated that single and double chain rt-PA (the latter
obtained by proteolytic cleavage) have very similar phar-
macokinetics (18).
Specific activities per milligram of protein of the two
fo rms of r(-PA. These are reported to be the same; a dif-
ference in specifi c activities, therefore, would not explain
the difference in reperfusion potency. Wallen et al. (21)
demonstrated with rt-PA from pig hearts that the double
chain form developed from the single chain form during
activation by protease. and that the fibrinolytic potencies of
both forms were very similar. Further. in a purified system
composed of fibrin and plasminogen. both forms of rt-PA
obtained from human melanoma cell cultures had equal
fibrinolytic activities (22). Electrophoretic studies by the
same investigators again revealed that the single chain rt-
PA was quickly converted to double chain rt-PA during
fibrinolysis (22). Thus, this conversion did not alter fibrin-
olytic activity. Recently. in vitro clot lysis assays established
that both the old and the new forms of rt-PA have the same
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specific activity, 600,000 IV/mg protein (Baughman R, PhD,
Genentech, Inc., personal communication).
Effects of the two forms of rt-PA on the fibrinolytic
system. It is interesting that, even though the coronary
reperfusion rates were comparable, the declines in plasma
fibrinogen and plasminogen levels were less with 100 mg
of the new form of rt-PA than with 80 mg of the old form.
There is a dissociation noted between the two effects of rt-
PA, namely, the effect on the fibrin clot occluding the coro-
nary artery and the fluid-phase effect on the systemic plasma
proteins. On the basis of differences in pharmacokinetics
between the old and new forms of rt-PA (19), it is pre-
dictable that the 40% higher dose of new rt-PA, combined
with the initial bolus injection, would achieve peak plasma
rt-PA levels and rt-PA delivery to the clot comparable with
those with old rt-PA. This is supported by the comparable
reperfusion rates with both dose regimens. In contrast to
the rapid binding of rt-PA to fibrin and the effective plasmin
formation on the clot surface, the plasmin generation in
plasma is strikingly slower because fibrinogen is ineffective
compared with fibrin in its ability to support plasminogen
activation by rt-PA. More importantly, the systemic effect
is dependent on the duration of the presence of rt-PA in the
circulation (23). Compared with old rt-PA, the shorter plasma
half-life of new rt-PA explains the lower systemic fibrino-
genolysis and the dissociation between the effects on coro-
nary reperfusion and plasma factors. However, this differ-
ential effect was no longer observed with the maximal 150
mg dose of new rt-PA and a prolonged infusion regimen,
6 hours compared with 3 hours.
Hemorrhagic events. Hemorrhagic events occurred fre-
quently in all four of these TIMI studies. Among them,
bleeding at vascular puncture sites predominated, account-
ing for approximately 70% of the events. Other causes for
major bleeding were rare. The mechanism for bleeding in
the setting of the TIMI protocol is complex. Intensive an-
ticoagulation interferes with the effective clot formation and
in the face of vascular punctures contributes importantly to
bleeding. Further, rt-PA not only dissolves occlusive clots
in coronary arteries, but also dissolves clots needed for
hemostasis at vascular puncture sites. In addition, the con-
tribution of the effect of rt-PA on plasma fibrinogen, leading
to the generation of fibrin(ogen) degradation products (FDP),
needs to be taken into account. The soluble degradation
products of fibrinogen and fibrin impair fibrin polymeriza-
tion (24,25) and thus function as anticoagulants. In the
present study, there was a significant relation between FDP
and bleeding events. These changes in the coagulation pro-
cess are compounded by impairment of platelet function,
induced by antiplatelet drugs, FDP (24,25) and plasmin
(26). Because the majority of bleeding occurred in relation
to vascular puncture sites, it is likely that the frequency of
bleeding complications will decrease significantly if throm-
bolytic therapy is initiated in the absence of invasive pro-
cedures.
The frequency of bleeding episodes in TIMI Phase I
(35%) is comparable with that in the European rt-PA trials
which reported an incidence of23% (3) and 26% (2). Bleed-
ing at vascular puncture sites predominated in all three stud-
ies, and major hemorrhagic events were rare. With increas-
ing doses of rt-PA, there is a trend to increased bleeding
complications in TIMI open label Studies A, Band C. The
introduction of percutaneous transluminal coronary angio-
plasty 18 to 48 hours after rt-PA infusion in Studies A, B
and C probably contributed to bleeding complications in
comparison with TIMI phase 1.
Conclusion. The consecutive studies provide informa-
tion about the old and new forms of rt-PA and about dose
finding for the new form which is relevant for future clinical
trials. The new form of rt-PA, produced on a large scale
basis, has less potency than the old form with regard to both
coronary reperfusion and systemic fibrinogenolysis. This is
attributed to its faster elimination from the circulation and
not to its different structure in relation to predominantly
single chain molecules compared with predominantly double
chain molecules of old rt-PA. The study demonstrated a
time- and dose-dependent relation between new rt-PA and
the potency of coronary recanalization and effects on sys-
temic fibrinogenolysis. The highest and most rapid rates of
reperfusion were achieved with the maximal 150 mg dose.
With this regimen and longer infusion time, systemic fi-
brinogenolysis increased to the level observed with old rt-
PA. Although the effect of rt-PA on the fibrinolytic system
varied considerably among the four study groups, bleeding
complications were similar. This observation suggests that
factors other than rt-PA, such as anticoagulants, antiplatelet
drugs and invasion of the vascular system, contribute to
bleeding events. The present study demonstrates the efficacy
of a high dose regimen of rt-PA, but also underlines that
the entire therapeutic regimen associated with thrombolysis
carries a certain risk requiring careful consideration for pa-
tient selection.
Addendum
Subsequent to TIMI Study C, a prerandomization pilot
study was performed before the initiation of TIMI Phase II.
In this study, 326 patients received the regimen of 150 mg
of new rt-PA including the initial bolus of 9 mg within 4
hours after clinical onset of infarction; intracerebral hem-
orrhage occurred in 5 (1.5%) of these in contrast to only 1
of 386 patients treated with rt-PA in prior TIMI protocols.
For this reason, the 150 mg dose was reduced to 100 mg
in the on-going TIMI Phase II study (27).
We appreciate the help of Virginia Wengerter in the preparation of the
manuscript.
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Appendix
Thrombolysis in Myocardial
Infarction (TIMI) Investigators
Study Chairman: Eugene Braunwald, MD, Harvard University, Boston.
Coordinating Center
Maryland Medical Research Institute, Baltimore, MD. Principal
Investigator: Genell L. Knatterud, PhD; Coinvestigators: William R. Bell,
MD, Paul L. Canner, PhD, Sandra Forman, MA, Dorothy T. Harris,
Leonard Scherlis, MD, Michael L. Terrin, MD, MPH, Pearl Van Natta,
MA, Patricia C. Wilkins, BS.
Radiographic Core Laboratory
University of Washington, Seattle, WA. Principal Investigator: Harold
T. Dodge, MD; Coinvestigators: B. Greg Brown, MD, PhD, J. Ward
Kennedy, MD, Florence H. Sheehan, MD.
Radionuclide Core Laboratory
Yale University, New Haven, CT. PrincipalInvestigator: BarryZaret,
MD; Coinvestigator: Frans Wackers, MD.
Coagulation Core Laboratory
Temple University, PhUadelphia,PA. Principal Investigator: A. Koneti
Rao, MD;Coinvestigators: RobertW. Colman, MD, AndreiZ. Budzynski,
PhD.
National Heart, Lung and Blood Institute Program Office
National Institutes of Health, Bethesda, MD. Principal Investigator:
Eugene R. Passamani, MD; Coinvestigators: Thomas L. Robertson, MD,
Janet T. Wittes, PhD.
Pathology Core Laboratory
National Institutes of Health ClinicalCenter, Bethesda, MD. Principal
Investigator: William C. Roberts, MD; Coinvestigator: Deborah Barbour.
MD.
Cooperative Studies Program
Clinical Research Pharmacy Coordinating Center, Albuquerque,
NM. PrincipalInvestigator: MichaelJ. Kovach, RPh;Coinvestigator: Clair
Haakenson, MS, RPh.
Clinical Centers
Albert Einstein College of Medicine, Montefiore Medical Center,
New York, NY. Principal Investigator: Hiltrud S. Mueller, MD;
Coinvestigators: Mark A. Greenberg, MD, Richard Grose, MD, Richard
Steingart, MD, Barbara Ventura, RN, Kathie Hemingway, RN.
Baylor College of Medicine, Houston, TX. Principal Investigator:
Robert Roberts, MD; Coinvestigators: Phyllis Bienvenue, RN, I. Kenneth
Inouye, MD, Jerry C. Luck, MD, Alfredo Montero, MD, Craig Pratt,
MD, Albert Raizner, MD, Mary Kay VanderMolen, RN, MarioS. Verani,
MD, James B. Young, MD.
BostonUniversityMedical Center, Boston, MA. Principal Investigator:
Thomas J. Ryan, MD; Coinvestigators: Carl S. Apstein, MD, David P.
Faxon, MD, Alice K. Jacobs, MD, Mirle A. Kellett, MD, Timothy A.
Sanborn, MD, James R. Wilentz, MD, Thomas Varricchione, RRT.
Brown University, Providence, RI. Principal Investigator: David O.
Williams, MD;Coinvestigators: RobertJ. Capone, MD, ThomasM. Drew,
MD, DianeL. Hardink, RN, Eric Berger, MD, StevenFera, MD, Raymond
S. Riley, MD, Nicholas A. Rucocco, MD, Harvey J. White, MD.
Columbia University, New York, NY. Principal Investigator: Eric
Powers, MD; Coinvestigators: Andrew Berke, MD, Edith Escala, RN,
Kenneth D. Friedman, MD, Lynne Johnson, MD, Mark Krischenbaum,
MD, John Owen, MD, Allen B. Nichols, MD, Dennis S. Reison, MD,
Allan Schwartz, MD, Rita Watson, MD.
Cornell Medical Center, New York, NY. Principal Investigator: Jeffrey
S. Borer,MD;Coinvestigators: DavidH. Miller, MD,Theodore L. Schreiber,
MD, Denise A. Silvasi, RN.
George Washington University, Washington, D.C, Principal
Investigator: Allan M. Ross, MD; Coinvestigators: George B. Bren, MD,
Teresa Bren, RN, Richard I. Katz, MD, Roy H. Leiboff, MD, Stanley
B. Schmidt, MD, Harry Schwartz, MD, P. Jacob Varghese, MD, Alan
G. Wasserman, MD, Molly Magee, RN.
Harvard University, Boston, MA. Principal Investigator: John E.
Markis, MD; Coinvestigators: James Alderman, MD, Cynthia Brewer,
RN, Raymond G. McKay, MD.
Mayo Foundation, Rochester, MN. Principal Investigator: James H.
Chesebro, MD; Coinvestigators: Dennis R. Bresnahan, MD, Bernard J.
Gersh, MD, LaVon Hammes, RN, Laurie Meyers, LPN, Fletcher A.
Miller, MD, Michael B. Mock, MD, Hugh C. Smith, MD, Diane Klees,
LPN.
University of Massachusetts, Worcester, MA. PrincipalInvestigator:
James E. Dalen, MD; Coinvestigators: Joseph S. Alpert, MD, Steven P.
BaiLRN, Joseph R. Benotti, MD, Paul Doherty, MD, Joel M. Gore, MD,
Ira S. Ockene, MD, James F. Rippe, MD, BonnieH. Weiner, MD, Jeanne
Corrao, RN.
UniversityofTexas, Dallas,TX. Principal Investigator: JamesWillerson,
MD; Coinvestigators: L. David Hillis, MD, George Revtyak, MD, Blair
Toates, RN, Michael Winniford, MD.
Washington University, St. Louis, MO. PrincipalInvestigator: Philip
A. Ludbrook, MD; Coinvestigators: Allan S. Jaffe, MD, Peter B. Kurnik,
MD, Nancy A. Ricciotti, RN, MSN, Burton E. Sobel, MD, James J.
Spadaro, MD, Allan J. Tiefenbrunn, MD.
Yale University, New Haven, CT. Principal Investigator: Charles K.
Francis, MD; Coinvestigators: Henry S. Cabin, MD, LawrenceS. Cohen,
MD, Caroline Piselli, RN, Daniel Wohlgelernter, MD, Joan Gerard-
Arnatruda, RN.
TIMI Committees: Open Label 85 Phases:
August 1985 to March 1986
ExecutiveCommittee: Dr. Eugene Braunwald, Chairman; Dr. Lawrence
Cohen, Dr. James Dalen, Dr. Harold Dodge, Dr. Genell Knatterud, Dr.
Eugene Passamani, Dr. A. Koneti Rao, Dr. Robert Roberts, Dr. Burton
Sobel, Dr. David Williams, Dr. Barry Zaret.
Mortality and Morbidity Classification Committee (MMCC): Dr.
James Chesebro, Chairman; Dr. Andrew Berke, Dr. Henry Cabin, Dr.
Joel Gore, Dr. L. David Hillis, Dr. Roy Leiboff, Dr. Craig Pratt, Dr.
Thomas Robertson, Dr. Michael Terrin.
Safetyand Data Monitoring Committee: Dr. Francis Klocke, Chairman;
Dr. RichardConti, Dr. David DeMets, Dr. ValentineFuster, Dr. Thomas
Killip, Dr. Harold Roberts, Dr. Leroy Walters.
Ex-officio Members: Dr. Eugene Braunwald, Dr. Genell Knatterud,
Dr. Eugene Passarnani, Dr. Thomas Robertson.
Steering Committee: Members of the Steering Committee are the
Study Chairman and Principal Investigators from TIMI Clinical Centers,
Core Laboratories, Coordinating Center and NHLBI Program Office.
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